BioSpace News Archive

Marine Biotechnology as Integral Part of the Circular Bioeconomy

The 11th EFIB attracted around 240 companies and stakeholders from 31 nations. EMBRIC joined the conference to speak about and highlight the potential of the blue biotechnology.

November 12, 2018
·
4 min read
29 October 2018 is World Psoriasis Day

Global campaign to support 125 million people worldwide highlights the seriousness of psoriasis and psoriatic arthritis.

November 12, 2018
·
4 min read
Deals

Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop CocoonTM Autologous Technology

Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies

November 12, 2018
·
4 min read
The 10ft tall microscopes helping combat world’s worst diseases

The century old mission to understand how the proteins responsible for amyloid-based diseases such as Alzheimer’s, Huntingdon’s and Parkinson’s work has taken major steps forward in the last 12 months, thanks to a revolution in a powerful microscopy technique used by researchers.

November 12, 2018
·
5 min read
Business

Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018

BioArctic AB to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at 08:00 a.m. CET.

November 12, 2018
·
1 min read
Business

A New Environment for Repairing Eyes

UH Expert to Bring Consistency to Corneal Stem Cell Fate

November 12, 2018
·
3 min read
Drug Development

InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing

InflaRx N.V. today announced that the first patient has been dosed in a phase II study to determine the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with ANCA-associated vasculitis (AAV).

November 12, 2018
·
5 min read
Deals

Takeda Sets a Date for Shareholders to Vote for the $62 Billion Acquisition of Shire

Pharma giant Takeda Pharmaceutical is looking to begin 2019 with a bang – closing its $62 billion acquisition of Shire plc by Jan. 8. This morning Takeda announced that it will hold an investor vote next month on the planned acquisition in order to swiftly move and finalize the deal.

November 12, 2018
·
3 min read
·
Alex Keown
Deals

Well-Funded Unicorn Moderna Therapeutics Eyes $500 Million IPO

As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).

November 12, 2018
·
2 min read
·
Alex Keown
Drug Development

Deep Dive: Immunovative Therapies’ Next-Generation Cancer Vaccine Could Change the Game

Checkpoint inhibitors are only effective against inflamed tumors, called ‘hot’ tumors. Unfortunately, most tumors are ‘cold’ (not inflamed) and hide from the immune system by appearing to be too similar to normal cells.

November 12, 2018
·
10 min read
·
Chelsea Weidman Burke